JAK
JAK (Janus kinase) inhibitors are compounds that target the JAK-STAT signaling pathway, which is involved in cell growth, immune response, and angiogenesis. By inhibiting JAK, these compounds can reduce the signaling that leads to the formation of new blood vessels in tumors, thereby inhibiting tumor growth. JAK inhibitors are important in the treatment of cancers and inflammatory diseases. At CymitQuimica, we offer a diverse range of high-quality JAK inhibitors to support your research in oncology, immunology, and angiogenesis.
Products of "JAK"
Sort by
TCS 21311
CAS:TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.Formula:C27H25F3N4O4Purity:≥98%Color and Shape:SolidMolecular weight:526.51Ruxolitinib (S enantiomer)
CAS:Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.Formula:C17H18N6Purity:99.37% - 99.79%Color and Shape:SolidMolecular weight:306.36JAK2-IN-9
CAS:Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM.Formula:C20H24N6O2SPurity:98%Color and Shape:SolidMolecular weight:412.514-(3'-HYDROXYPHENYL)AMINO-6,7-DIMETHOXYQUINAZOLINE, HCL
CAS:Formula:C16H16ClN3O3Purity:97.0%Molecular weight:333.7695AG490
CAS:AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.Formula:C17H14N2O3Purity:98.6% - 99.39%Color and Shape:Yellow SolidMolecular weight:294.3BD750
CAS:BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM inFormula:C14H13N3OSPurity:99.02%Color and Shape:SolidMolecular weight:271.34WHI-P180 Hydrochloride
CAS:Formula:C16H15N3O3·HClPurity:>97.0%(T)(HPLC)Color and Shape:White to Light gray to Light yellow powder to crystalMolecular weight:333.77Fedratinib hydrochloride hydrate
CAS:Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.Formula:C27H40Cl2N6O4SPurity:98.96% - 99.46%Color and Shape:SolidMolecular weight:615.61JAK-IN-3
CAS:JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.Formula:C18H20N4O3Purity:98.04% - 98.19%Color and Shape:SolidMolecular weight:340.38Ref: TM-T11704
1mg133.00€2mg188.00€5mg321.00€10mg518.00€25mg1,035.00€50mg1,644.00€100mg2,680.00€200mg3,591.00€1mL*10mM (DMSO)354.00€Momelotinib Mesylate
CAS:Momelotinib Mesylate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.Formula:C24H26N6O5SPurity:98%Color and Shape:SolidMolecular weight:510.57Delgocitinib
CAS:Delgocitinib is a potent JAK inhibitor (IC50: 2.8-58 nM), treats inflammatory diseases, and is the first topical drug for atopic dermatitis.Formula:C16H18N6OPurity:99.90%Color and Shape:SolidMolecular weight:310.35Ref: TM-T15096
1mg169.00€5mg311.00€10mg487.00€25mg929.00€50mg1,415.00€100mg2,062.00€200mg2,775.00€1mL*10mM (DMSO)349.00€CP-352664
CAS:CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.Formula:C18H18N4Color and Shape:SolidMolecular weight:290.36LFM-A13
CAS:LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR,Formula:C11H8Br2N2O2Purity:99.9%Color and Shape:SolidMolecular weight:360JAK1-IN-10
CAS:JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].Formula:C15H17N7Purity:98%Color and Shape:SolidMolecular weight:295.34Tyk2-IN-20
CAS:Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.Formula:C24H25N7O2Color and Shape:SolidMolecular weight:443.50Brepocitinib
CAS:Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).Formula:C18H21F2N7OPurity:99.8%Color and Shape:SolidMolecular weight:389.4Ref: TM-TQ0010
1mg35.00€5mg74.00€10mg110.00€25mg226.00€50mg411.00€100mg660.00€200mg917.00€1mL*10mM (DMSO)81.00€RO8191
CAS:RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.Formula:C14H5F6N5OPurity:98.85% - ≥98%Color and Shape:SolidMolecular weight:373.21MM-589 TFA
CAS:MM-589 TFA is a potent WD repeat domain 5 (WDR5)inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Formula:C30H45F3N8O7Purity:98%Color and Shape:SolidMolecular weight:686.72Atractylenolide I
CAS:Atractylenolide-I reduces inflammation, improves sepsis, liver, and kidney function, and enhances EOC cell sensitivity to paclitaxel.Formula:C15H18O2Purity:97.55% - 99.83%Color and Shape:SolidMolecular weight:230.3AJI-214
CAS:AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).Formula:C17H13ClFN5OColor and Shape:SolidMolecular weight:357.77
